COMPANY

Syntis Bio Inc.

HQ: Boston, MA source · syntis.bio ↗ · New England

Keywords: rare disease metabolic obesity homocystinuria

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

9NIH grants

NIH awards 9

Annual award amounts. Total $6.0M.

Aug 10, 2026 NIH award 5R44DK141341-03 FY2026: $916,664 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Development of an Oral Pill to Mimic the Effects source ↗
May 26, 2026 NIH award 5R44DK138869-03 FY2026: $1,190,375 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Polymer Epithelial Lining for the Oral Delivery source ↗
Sep 16, 2025 NIH award 1R44HD118842-01A1 FY2025: $347,016 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Development of an Oral Methionine-Gamma-Lyase E source ↗
Sep 8, 2025 NIH award 1R44DK143766-01 FY2025: $343,635 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Development of Once-daily Oral Treatment for Mapl source ↗
Jul 23, 2025 NIH award 1R44DK142244-01 FY2025: $324,984 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Oral Therapeutics Platform for Treating Inborn Er source ↗
Jul 2, 2025 NIH award 4R44DK141341-02 FY2025: $916,400 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Development of an Oral Pill to Mimic the Effects source ↗
May 28, 2025 NIH award 4R44DK138869-02 FY2025: $1,245,529 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Polymer Epithelial Lining for the Oral Delivery source ↗
Sep 12, 2024 NIH award 1R44DK141341-01 FY2024: $322,787 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Development of an Oral Pill to Mimic the Effects source ↗
Apr 24, 2024 NIH award 1R44DK138869-01A1 FY2024: $349,160 awarded for that fiscal year; activity R44 (SBIR); PI SETHURAMAN, VASU V; recipient as written: SYNTIS BIO INC, Boston, MA. Polymer Epithelial Lining for the Oral Delivery source ↗

Funding and NIH signals

NIH award NIH awarded $917K (SBIR Phase II 5R44DK141341-03, continuation, notice Aug 10, 2026); 2 NIH awards totaling $2.11M in the last 12 months. NIH RePORTER 5R44DK141341-03 (Aug 10, 2026)
Evidence (2 events)
- Aug 10, 2026 · NIH RePORTER 5R44DK141341-03
  Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK141341-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 916664; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery; Organization type: Domestic For-Profits
- May 26, 2026 · NIH RePORTER 5R44DK138869-03
  Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK138869-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1190375; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Polymer Epithelial Lining for the Oral Delivery of Macromolecules; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals